In one study, pioglitazone was added to the treatment of three CML patients, two of which also had type II diabetes, who had not reached a complete molecular response (CMR) (defined as undetectable BCR::ABL1 by RT-qPCR) after 4–6 years on imatinib [71]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.